Financial Performance Highlights

  • Revenue Growth: Revenue from operations surged 36% to ₹500.95 crores (standalone ₹488.77 crores) from previous year
  • Profitability: EBITDA more than doubled to ₹72.69 crores while PAT grew 128% to ₹48.13 crores (standalone ₹41.40 crores)
  • Dividend: Board recommended final dividend of ₹1.75 per equity share, involving cash outflow of ₹108.12 lakh
  • Balance Sheet: Total assets stood at ₹545.50 crore with shareholders' funds of ₹329.23 crore and debt-equity ratio of 0.33

Expansion and Capital Expenditure

  • Tarapur Project: Greenfield expansion revised to ₹210 crore budget with ₹182.75 crore already invested as of Q4FY26
  • Progress: Phase I completed and operational; Phase II commissioning expected in Q2FY27 with commercial production from H2FY27
  • Facility Features: Designed for regulated markets with advanced utilities and cleanroom infrastructure
  • Capital Work-in-Progress: Significantly increased to ₹94.57 crore, indicating major ongoing capacity expansion

Operational and Regulatory Highlights

  • Export Focus: 74% of total revenue from exports, serving approximately 430 customers across 55+ countries
  • Regulatory Approvals: Three CEPs approved, five ASMF approvals in Europe, and three VMF filings for United States
  • Quality Record: Maintained 15-year record of zero market rejections across 45 APIs manufactured
  • Manufacturing: 5 facilities with 75% production from zero liquid discharge facilities

Corporate Governance and Compliance

  • SEBI Settlement: Paid ₹54.42 lakh to settle matters related to incorrect shareholding pattern disclosures from December 2002 to June 2019
  • Board Composition: 6 directors including 3 independent and 2 women directors; 4 Board meetings held during the year
  • CSR Activities: Expenditure of ₹41.50 lakh benefiting 3000+ beneficiaries, though short of required ₹51.61 lakh
  • AGM Details: Scheduled for August 25, 2026 with record date for dividend on August 18, 2026

Financial Structure and Borrowings

  • Funding Mix: Expansion project funded through mix of debt and internal accruals
  • Term Loans: ₹56.40 crore from HDFC Bank and Kotak Mahindra Bank at 7.73%-8% interest rates
  • Security: Mortgaged leasehold land & buildings at Tarapur with personal guarantees from MD and Executive Director
  • Subsidiary: Investment of ₹3.73 crore and loan of ₹12.65 crore to Macrotech Polychem Private Limited

Subsequent Events and Outlook

The company has progressed validation batches across multiple products and maintains strong relationships with 5 of top 10 global animal healthcare companies. The expansion project positions NGL Fine-Chem for continued growth in regulated markets with enhanced manufacturing capabilities expected to drive future revenue growth.